Boehringer Ingelheim and Eli Lilly and Company have launched Glyxambi (empagliflozin/linagliptin) tablets in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. Glyxambi, part of the diabetes alliance portfolio of Boehringer Ingelheim Pharmaceuticals and Lilly is a dual inhibitor combination therapy approved in the US that combines the mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet. SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney. DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose.

Glyxambi is approved as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments. Glyxambi is a once-daily tablet taken in the morning that combines 10 mg or 25 mg of empagliflozin, an SGLT2 inhibitor, with 5 mg of linagliptin, a DPP-4 inhibitor. The drug was approved by the US Food and Drug Administration in February 2015.

Source: Eli Lilly